Neu­roRx se­cures $95M to fund PhI­II for NM­DA de­pres­sion drug; Trump re­vives sci­ence ad­vi­so­ry coun­cil

→ Af­ter kick­ing off a Phase III tri­al test­ing its NM­DA drug in sui­ci­dal bipo­lar de­pres­sion, Neu­roRx has se­cured ac­cess to around $95 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.